文献速递胸部肿瘤支持与姑息治疗

泛癌种中STK11变异的预后与治疗意义

STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications.
PubMed 文献 · Eur J Cancer · 2021-03-19

本研究分析4446例接受组织或ctDNA二代测序的患者,发现1.35%存在STK11变异。泛癌种中STK11变异与更短至进展时间和总生存相关,但单独STK11变异不影响免疫治疗结局;STK11/KRAS共变异患者无论治疗类型预后均更差。

要点

  • 泛癌种中STK11变异频率为1.35%(60/4446)。
  • STK11变异与泛癌种更短TTP和OS相关,与治疗类型无关。
  • STK11/KRAS共变异者一线治疗PFS和OS更差,免疫治疗亦更差。

核心结论

  • 泛癌种中STK11变异与不良预后相关,但单独STK11变异不伴随免疫治疗结局变差。
  • STK11/KRAS共变异患者无论治疗类型均预后更差。

研究设计与样本

  • 回顾性分析4446例接受组织或ctDNA二代测序的泛癌种患者。

主要发现

  • 60/4446(1.35%)肿瘤携带STK11变异。
  • STK11变异者中位至进展时间6.4个月(5.1-7.9)对12个月(11.7-12.3),p=0.001;中位OS 20.5个月(17.4-23.5)对29.1个月(26.9-31.3),p=0.03。
  • STK11/KRAS共变异者(N=27)一线治疗中位PFS 3个月(1.3-4.7)对STK11变异/KRAS野生型(N=33)10个月(4.9-15.7),p<0.0005,多因素p=0.06;中位OS亦更短(多因素p=0.02)。
  • 免疫检查点阻断治疗中,STK11/KRAS共变异对STK11变异/KRAS野生型中位PFS更短(p=0.04),OS有更短趋势(p=0.06)。
  • 免疫治疗中STK11变异对野生型泛癌种PFS(p=0.4)和OS(p=0.7)无差异;STK11变异肺癌患者免疫治疗亦未更差。

临床怎么用

  • 泛癌种中检测STK11变异有助于预后分层,尤其关注KRAS共变异状态。
  • STK11/KRAS共变异患者应优先考虑非免疫治疗策略或临床试验。
  • 单独STK11变异不应作为泛癌种或NSCLC免疫治疗排除标准。

局限性

  • 回顾性研究设计。
  • STK11/KRAS共变异亚组样本量小(N=27和N=33)。
  • 多因素分析中部分P值未达统计学显著性(如一线PFS多因素p=0.06)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: STK11 is an important tumour suppressor gene reported to confer immunotherapy resistance in non-small-cell lung cancers (NSCLC) especially in the presence of KRAS co-alterations. METHODS: This study analysed 4446 patients for whom next-generation sequencing of tissue and/or circulating tumour DNA (ctDNA) had been performed. RESULTS: Overall, 60 of 4446 tumours (1.35%) harboured STK11 alterations. STK11 alterations were associated with shorter median time to progression and overall survival (OS) across cancers from diagnosis: 6.4 months (5.1-7.9) versus 12 months (11.7-12.3; p = 0.001); and 20.5 (17.4-23.5) versus 29.1 (26.9-31.3; p = 0.03), respectively (pan-cancer). Pan-cancers, the median progression-free survival (PFS; 95% CI) for first-line therapy (regardless of treatment type) for those with co-altered STK11 and KRAS (N = 27; versus STK11-altered and KRAS wild type [N = 33]), was significantly shorter (3 [1.3-4.7] versus 10 [4.9-15.7] months, p < 0.0005, p multivariate, 0.06); the median OS also was also shorter (p multivariate = 0.02). In pan-cancer patients treated with checkpoint blockade, STK11 and KRAS co-altered versus STK11-altered/KRAS wild type had a shorter median PFS and trend toward shorter OS (p = 0.04 and p = 0.06, respectively). In contrast, in examining STK11-altered versus wild-type pan-cancer patients treated with checkpoint blockade immunotherapy, the two groups showed no difference in outcome (PFS [p = 0.4]; OS [p = 0.7]); STK11-altered versus wild-type lung cancer patients also did not fare worse on immunotherapy. CONCLUSIONS: Across cancers, STK11 alterations correlated with a poor prognosis regardless of therapy. However, STK11 alterations alone did not associate with inferior immunotherapy outcome in the pan-cancer setting or in NSCLC. Pan-cancer patients with co-altered STK11/KRAS did worse, regardless of treatment type.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Krishnamurthy N, Goodman AM, Barkauskas DA, et al. STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications. Eur J Cancer. 2021. PMID: 33744718. doi:10.1016/j.ejca.2021.01.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。